Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Phase 1b: Primary Objective: - To determine the recommended Phase 2 dose (RP2D) of ibrutinib in combination with everolimus in RCC, paclitaxel in urothelial carcinoma, docetaxel in gastric adenocarcinoma and cetuximab in CRC. Phase 2: Primary Objectives: - To assess progression-free survival (PFS) of ibrutinib combination therapy in RCC and urothelial carcinoma, and to assess the ORR of ibrutinib combination therapy in gastric adenocarcinoma and CRC
Inclusion criteria
- Metastatic renal cell carcinoma (RCC), advanced urothelial carcinoma, advanced gastric (including gastro-esophageal [GEJ]) adenocarcinoma, and metastatic colorectal adenocarcinoma (CRC)